Animal Models in Cardiovascular MRI Research: Value and Limitations

Current Cardiovascular Imaging Reports

Volumn 5, Issue 2, 2012, Pages 99-108

  French, Brent A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Animal models; Cardiovascular disease; Magnetic resonance imaging; Translational medicine

Indexed keywords

EID: 84873882859     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-012-9128-6     Document Type: Review

References (42)

1. Rogers Jr WJ, Shapiro EP, Weiss JL, Buchalter MB, Rademakers FE, Weisfeldt ML, et al. Quantification of and correction for left ventricular systolic long-axis shortening by magnetic resonance tissue tagging and slice isolation. Circulation. 1991; 84(2): 721-31.
2. Mostbeck GH, Caputo GR, Higgins CB. MR measurement of blood flow in the cardiovascular system. AJR Am J Roentgenol. 1992; 159(3): 453-61.
3. Bennett KM, Shapiro EM, Sotak CH, Koretsky AP. Controlled aggregation of ferritin to modulate MRI relaxivity. Biophys J. 2008; 95(1): 342-51.
4. Harrison GJ, Cerniway RJ, Peart J, Berr SS, Ashton K, Regan S, et al. Effects of A(3) adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc Res. 2002; 53(1): 147-55.
5. Schuster A, Grunwald I, Chiribiri A, Southworth R, Ishida M, Hay G, et al. An isolated perfused pig heart model for the development, validation and translation of novel cardiovascular magnetic resonance techniques. J Cardiovasc Magn Reson. 2010; 12: 53.
6. Goldberg AM, Zurlo J, Rudacille D. The three Rs and biomedical research. Science. 1996; 272(5267): 1403.
7. Carmeliet P, Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol. 2000; 190(3): 387-405.
8. Epstein FH. MR in mouse models of cardiac disease. NMR Biomed. 2007; 20(3): 238-55.
9. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011; 474(7351): 337-42.
10. Initial sequencing and comparative analysis of the mouse genome. Nature. 2002; 420(6915): 520-62.
11. Bockamp E, Sprengel R, Eshkind L, Lehmann T, Braun JM, Emmrich F, et al. Conditional transgenic mouse models: from the basics to genome-wide sets of knockouts and current studies of tissue regeneration. Regen Med. 2008; 3(2): 217-35.
12. Huang G, Ashton C, Kumbhani DS, Ying Q-L. Genetic manipulations in the rat: progress and prospects. Curr Opin Nephrol Hypertens. 2011; 20(4): 391-9.
13. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res. 1998; 39(1): 60-76.
14. Decking UKM, Pai VM, Bennett E, Taylor JL, Fingas CD, Zanger K, et al. High-resolution imaging reveals a limit in spatial resolution of blood flow measurements by microspheres. Am J Physiol Heart Circ Physiol. 2004; 287(3): H1132-40.
15. Lawton J, Cupps B, Knutsen A, Ma N, Brady B, Reynolds L, et al. Magnetic resonance imaging detects significant sex differences in human myocardial strain. Biomed Eng Online. 2011; 10(76): 1-11.
16. Spence AL, Naylor LH, Carter HH, Buck CL, Dembo L, Murray CP et al. A prospective randomised longitudinal MRI study of left ventricular adaptation to endurance and resistance exercise training in humans. J Physiol. 2011; Published online before print.
17. Hockings P. Magnetic resonance imaging in pharmaceutical safety assessment. In: Vogel HG, editor. Drug discovery and evaluation: safety and pharmacokinetic assays. Berlin: Springer-Verlag; 2006. p. 385-408.
18. Franco F, Thomas GD, Giroir B, Bryant D, Bullock MC, Chwialkowski MC, et al. Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor alpha. Circulation. 1999; 99(3): 448-54.
19. Goetschalckx K, Rademakers F, Bogaert J. Right ventricular function by MRI. Curr Opin Cardiol. 2010; 25(5): 451-5.
20. Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S, et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation / Clinical Perspective. Circ Cardiovasc Imaging. 2010; 3(3): 231-9.
21. Makowski M, Jansen C, Webb I, Chiribiri A, Nagel E, Botnar R, et al. First-pass contrast-enhanced myocardial perfusion MRI in mice on a 3-T clinical MR scanner. Magn Reson Med. 2010; 64(6): 1592-8.
22. Zun Z, Wong EC, Nayak KS. Assessment of myocardial blood flow (MBF) in humans using arterial spin labeling (ASL): Feasibility and noise analysis. Magn Reson Med. 2009; 62(4): 975-83.
23. Matheijssen NA, Baur LH, Reiber JH, van der Velde EA, van Dijkman PR, van der Geest RJ, et al. Assessment of left ventricular volume and mass by cine magnetic resonance imaging in patients with anterior myocardial infarction intra-observer and inter-observer variability on contour detection. Int J Card Imaging. 1996; 12(1): 11-9.
24. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995; 8(3): 221-8.
25. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000; 2(4): 271-8.
26. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985; 57(1): 84-95.
27. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. New Engl J Med. 1988; 319(2): 80-6.
28. Pfeffer MA, Braunwald E, Moya LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med. 1992; 327(10): 669-77.
29. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006; 27(20): 2400-5.
30. Maurer G. Adenosine as an adjunct to reperfusion in myocardial infarction. Eur Heart J. 2006; 27(20): 2376-7.
31. • Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011; 32(7): 867-77. This report nicely illustrates the utility of combining T2-weighted and contrast-enhanced sequences to determine the myocardial salvage index for evaluating drug efficacy in the setting of acute MI.
32. • Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling: a new classification of biomarkers. Pharmaceut Res. 2005; 22(9): 1432-7. This article proposes a new classification scheme for biomarkers and discusses their application in mechanism-based PK/PD analysis for drug discovery and development.
33. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med. 2003; 348(14): 1309-21.
34. •• van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010; 7(3): e1000245. This review addresses the controversy surrounding the value of animal models in predicting the effectiveness of novel therapies in human trials and proposes practical strategies to improve their predictive value.
35. Guerette B, Moisset PA, Huard C, Tardif F, Gravel C, Tremblay JP. Inflammatory damage following first-generation replication-defective adenovirus controlled by anti-LFA-1. J Leukoc Biol. 1997; 61(4): 533-8.
36. Bodenheimer T. Uneasy alliance - clinical investigators and the pharmaceutical industry. N Eng J Med. 2000; 342(20): 1539-44.
37. Horrobin DF. Innovation in the pharmaceutical industry. JRSM. 2000; 93(7): 341-5.
38. •• Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R& D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9(3): 203-14. This review presents a detailed analysis of industry-wide data that characterizes the relative contributions of each step in the drug discovery/development pathway to overall productivity, then proposes specific strategies for improving that productivity.
39. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004; 3(8): 711-6.
40. Yang Y, Adelstein SJ, Kassis AI. Target discovery from data mining approaches. Drug Discov Today. 2009; 14(3-4): 147-54.
41. Rudy Y, Ackerman MJ, Bers DM, Clancy CE, Houser SR, London B, et al. Systems approach to understanding electromechanical activity in the human heart. Circulation. 2008; 118(11): 1202-11.
42. Phillips KA, van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov. 2006; 5(6): 463-9.